CounterAct

Product NDC
54473-184
11-digit product format
544730184
Labeler code
54473
Product ID
54473-184_994f4954-8668-606b-e053-2a95a90a5c50
Type
HUMAN OTC DRUG
Nonproprietary name
Acetaminophen, Diphenydramine HCI, Phenylephrine HCI
Dosage form
TABLET, COATED
Route
ORAL
Labeler
Melaleuca, Inc.
Application
part341
Marketing category
OTC MONOGRAPH FINAL
Marketing start
2011-08-01
Marketing end
2019-12-31
Substance
ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE
Active strength
325 mg/1; mg/1; mg/1
NDC exclude flag
No
Listing certified through
0000-00-00
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct54473-184DDiscontinued by firm2026-10-05
excluded packagepackage54473-18454473-184-36DDiscontinued by firm2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 24 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source dateDatasetScopePackage NDCSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05excluded productproductd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage54473-184-36d630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26excluded productproductf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage54473-184-36f5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-31excluded productproduct2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage54473-184-362ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28excluded productproducta1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage54473-184-36a1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21excluded productproductcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage54473-184-36cfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10excluded productproductcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage54473-184-36cdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31excluded productproduct302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage54473-184-36302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20excluded productproducted331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage54473-184-36ed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-10excluded productproduct0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage54473-184-360efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08excluded productproductad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage54473-184-36ad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03excluded productproduct367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage54473-184-36367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09excluded productproduct557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage54473-184-36557ba5c1ecfa…9c80585c8c6e…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
ACETAMINOPHENACTIVE INGREDIENT362O9ITL9DCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
DIPHENHYDRAMINE HYDROCHLORIDEACTIVE INGREDIENTTC2D6JAD40COUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
PHENYLEPHRINE HYDROCHLORIDEACTIVE INGREDIENT04JA59TNSJCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
ACETAMINOPHENACTIVE MOIETY362O9ITL9DCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
DIPHENHYDRAMINEACTIVE MOIETY8GTS82S83MCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
PHENYLEPHRINEACTIVE MOIETY1WS297W6MVCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61UCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
CROSCARMELLOSE SODIUMINACTIVE INGREDIENTM28OL1HH48COUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
CROSPOVIDONEINACTIVE INGREDIENT68401960MKCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBDCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
HYDROXYPROPYL CELLULOSEINACTIVE INGREDIENTRFW2ET671PCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
HYPROMELLOSESINACTIVE INGREDIENT3NXW29V3WOCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I30COUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
POLYETHYLENE GLYCOLINACTIVE INGREDIENT3WJQ0SDW1ACOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
POVIDONEINACTIVE INGREDIENTFZ989GH94ECOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU4COUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
STARCH, CORNINACTIVE INGREDIENTO8232NY3SJCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65APCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JPCOUNTERACT NIGHT (ACETAMINOPHEN, DIPHENYDRAMINE HCI, PHENYLEPHRINE HCI) TABLET, COATED [MELALEUCA, INC.]1